Current Cardiology Reports最新文献_第3页

Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure. 精准基因疗法：平衡心力衰竭患者的风险与收益。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-08-07 DOI: 10.1007/s11886-024-02096-5

Jamie R Johnston, Eric D Adler

{"title":"Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure.","authors":"Jamie R Johnston, Eric D Adler","doi":"10.1007/s11886-024-02096-5","DOIUrl":"10.1007/s11886-024-02096-5","url":null,"abstract":"Purpose of review: Precision genetic medicine is evolving at a rapid pace and bears significant implications for clinical cardiology. Herein, we discuss the latest advancements and emerging strategies in gene therapy for cardiomyopathy and heart failure.Recent findings: Elucidating the genetic architecture of heart failure has paved the way for precision therapies in cardiovascular medicine. Recent preclinical studies and early-phase clinical trials have demonstrated encouraging results that support the development of gene therapies for heart failure arising from a variety of etiologies. In addition to the discovery of new therapeutic targets, innovative delivery platforms are being leveraged to improve the safety and efficacy of cardiac gene therapies. Precision genetic therapy represents a potentially safe and effective approach for improving outcomes in patients with heart failure. It holds promise for radically transforming the treatment paradigm for heart failure by directly targeting the underlying etiology. As this new generation of cardiovascular medicines progress to the clinic, it is especially important to carefully evaluate the benefits and risks for patients.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing a 'Lead [Apron]-Free' Cardiac Catheterization: Current Status. 实施 "无导联[围裙]"心导管检查：现状。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-25 DOI: 10.1007/s11886-024-02102-w

Akash H Patel, Vishal Patel, Yicheng Tang, Sai Shah, George Tang, Morton J Kern

引用次数: 0

Unraveling the Complex Relationship-Atrial Fibrillation and Pulmonary Hypertension. 解开复杂的关系--心房颤动与肺动脉高压。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1007/s11886-024-02089-4

Kanishk Aggarwal, Pushkar S Valleru, F N U Anamika, Priyanka Aggarwal, Ira Gupta, Vasu Gupta, Nikita Garg, Rohit Jain

{"title":"Unraveling the Complex Relationship-Atrial Fibrillation and Pulmonary Hypertension.","authors":"Kanishk Aggarwal, Pushkar S Valleru, F N U Anamika, Priyanka Aggarwal, Ira Gupta, Vasu Gupta, Nikita Garg, Rohit Jain","doi":"10.1007/s11886-024-02089-4","DOIUrl":"10.1007/s11886-024-02089-4","url":null,"abstract":"Purpose of review: In this article, we underscore the importance of identifying risk factors and monitoring pulmonary hypertension patients for signs of arrhythmias, as this proactive approach can reduce morbidity and mortality.Recent findings: Atrial fibrillation is the most prevalent among cardiac arrhythmias and is associated with an increased risk of stroke, morbidity, and mortality. Smoking, obesity, hypertension, a sedentary lifestyle, and diabetes mellitus are some of the modifiable risk factors for atrial fibrillation. Recent studies show that the risk of atrial fibrillation is rising in patients with parenchymal and vascular lung disease. Stretching in the atria and pulmonary veins may lead to the onset of atrial fibrillation in cardiac conditions like hypertension, heart failure, and valvular disease. Atrial fibrillation in patients with pulmonary hypertension (PH) denotes a more advanced disease. Patients with PH are more susceptible to hemodynamic stress caused by tachycardia and an uncoordinated atrioventricular contraction. Therefore, atrial arrhythmias need to be treated because inadequate control of cardiac arrhythmias may result in poor clinical outcomes and lead to disease progression in PH patients. Aside from being a sign of severe disease, AF can also speed up and exacerbate the condition.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation? 因子 XI 抑制剂能否取代目前的抗凝药预防心房颤动患者中风？

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI: 10.1007/s11886-024-02100-y

Siddharth M Patel, Christian T Ruff

引用次数: 0

Obesity Paradox in Transcatheter Aortic Valve Replacement. 经导管主动脉瓣置换术中的肥胖悖论。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.1007/s11886-024-02098-3

Luai Madanat, Ahmad Jabri, Ivan D Hanson, Houman Khalili, Josep Rodés-Cabau, Thomas Pilgrim, Taishi Okuno, Sammy Elmariah, Philippe Pibarot, Pedro Villablanca, Amr E Abbas

{"title":"Obesity Paradox in Transcatheter Aortic Valve Replacement.","authors":"Luai Madanat, Ahmad Jabri, Ivan D Hanson, Houman Khalili, Josep Rodés-Cabau, Thomas Pilgrim, Taishi Okuno, Sammy Elmariah, Philippe Pibarot, Pedro Villablanca, Amr E Abbas","doi":"10.1007/s11886-024-02098-3","DOIUrl":"10.1007/s11886-024-02098-3","url":null,"abstract":"Background: Obesity paradox in cardiovascular risk prediction has gained increasing attention in recent years. We aimed to investigate the impact of BMI on mortality following transcatheter aortic valve replacement (TAVR).Methods: We performed a multi-center retrospective analysis of patients with severe aortic stenosis undergoing TAVR. Patients were categorized into: Underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥ 30). Multivariate cox-proportional hazard model was used to compare all-cause mortality.Results: Total of 6688 patients included (175 underweight, 2252 normal weight, 2368 overweight and 1893 with obesity). Mean age of patients was 81 ± 8 years with 55% males. Patients with obesity had higher prevalence of comorbidities but a lower overall STS score. Mortality at 30-days post-TAVR was lower in the obese population compared to underweight, normal weight, and overweight patients (1.6% vs. 6.9%, 3.6%, and 2.8%, respectively, p < 0.001). Similarly, 3-year mortality was lowest in patients with obesity (17.1% vs. 28.9%, 24.5% and 18.6%, respectively, p < 0.001). On multivariate analysis, long term all-cause mortality at 3-years remained significantly lower in patients with obesity compared to underweight (HR 1.74, 95% CI: 1.30-2.40, p < 0.001) and normal weight (HR: 1.41, 95% CI:1.21-1.63, p < 0.001) but not in overweight patients (HR: 1.10, 95% CI:0.94-1.28, p = 0.240).Conclusion: In conclusion, patients with obesity have improved short and long term mortality following TAVR with an observed progressive increase in mortality with lower BMI ranges.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electrophysiological Cardiovascular Magnetic Resonance (EP-CMR)-Guided Interventional Procedures: Challenges and Opportunities. 电生理心血管磁共振（EP-CMR）引导的介入手术：挑战与机遇。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-18 DOI: 10.1007/s11886-024-02092-9

Sabrina Oebel, Cosima Jahnke, Kerstin Bode, Ingo Paetsch

{"title":"Electrophysiological Cardiovascular Magnetic Resonance (EP-CMR)-Guided Interventional Procedures: Challenges and Opportunities.","authors":"Sabrina Oebel, Cosima Jahnke, Kerstin Bode, Ingo Paetsch","doi":"10.1007/s11886-024-02092-9","DOIUrl":"10.1007/s11886-024-02092-9","url":null,"abstract":"Purpose of review: Cardiovascular magnetic resonance (CMR) imaging excels in providing detailed three-dimensional anatomical information together with excellent soft tissue contrast and has already become a valuable tool for diagnostic evaluation, electrophysiological procedure (EP) planning, and therapeutical stratification of atrial or ventricular rhythm disorders. CMR-based identification of ablation targets may significantly impact existing concepts of interventional electrophysiology. In order to exploit the inherent advantages of CMR imaging to the fullest, CMR-guided ablation procedures (EP-CMR) are justly considered the ultimate goal.Recent findings: Electrophysiological cardiovascular magnetic resonance (EP-CMR) interventional procedures have more recently been introduced to the CMR armamentarium: in a single-center series of 30 patients, an EP-CMR guided ablation success of 93% has been reported, which is comparable to conventional ablation outcomes for typical atrial flutter and procedure and ablation time were also reported to be comparable. However, moving on from already established workflows for the ablation of typical atrial flutter in the interventional CMR environment to treatment of more complex ventricular arrhythmias calls for technical advances regarding development of catheters, sheaths and CMR-compatible defibrillator equipment. CMR imaging has already become an important diagnostic tool in the standard clinical assessment of cardiac arrhythmias. Previous studies have demonstrated the feasibility and safety of performing electrophysiological interventional procedures within the CMR environment and fully CMR-guided ablation of typical atrial flutter can be implemented as a routine procedure in experienced centers. Building upon established workflows, the market release of new, CMR-compatible interventional devices may finally enable targeting ventricular arrhythmias.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes? FDG-PET 成像能否识别心脏肉样瘤病的疾病表型？

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s11886-024-02086-7

Kevin Emery Boczar, Yooyhun Park, Christiane Wiefels

{"title":"Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?","authors":"Kevin Emery Boczar, Yooyhun Park, Christiane Wiefels","doi":"10.1007/s11886-024-02086-7","DOIUrl":"10.1007/s11886-024-02086-7","url":null,"abstract":"Purpose of review: Despite the scarcity of data, most guidelines have advocated for the treatment of cardiac sarcoidosis with corticosteroids. However, there is heterogeneity in disease presentation and response to treatment, which can make treatment challenging. The ability to identify disease phenotypes to allow for tailored therapy is therefore highly desirable. This review will seek to outline the disease phenotypes of cardiac sarcoidosis and the role that FDG-PET imaging can play in identifying these phenotypes to optimize disease diagnosis and treatment management.Recent findings: FDG PET can identify cardiac sarcoidosis and is being increasingly used to monitor therapeutic response to immunosuppressive therapy, to follow treatment response after discontinuation of corticosteroid therapy, and to evaluate for disease relapse. Modern quantitative techniques using FDG PET imaging may allow for even better phenotypic disease characterization and the ability to track the response to immunosuppression more accurately. FDG PET currently plays an important role in cardiac sarcoidosis diagnosis. However, it also affords us the opportunity to offer insights into cardiac sarcoidosis disease phenotypes to better understand the underlying disease process and in the future may allows us to tailor therapies accordingly.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Regulation of Cardiac Conduction System Development. 心脏传导系统发育的分子调控

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s11886-024-02094-7

Lucie Boulgakoff, Gaetano D'Amato, Lucile Miquerol

引用次数: 0

Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer. 癌症治疗中的心血管毒性：在抗癌的同时保护心脏。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI: 10.1007/s11886-024-02099-2

Amit Manhas, Dipti Tripathi, Dilip Thomas, Nazish Sayed

{"title":"Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer.","authors":"Amit Manhas, Dipti Tripathi, Dilip Thomas, Nazish Sayed","doi":"10.1007/s11886-024-02099-2","DOIUrl":"10.1007/s11886-024-02099-2","url":null,"abstract":"Purpose of review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.Recent findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure. 如何优化心力衰竭患者的目标导向医疗疗法 (GDMT)。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.1007/s11886-024-02101-x

Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky

{"title":"How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.","authors":"Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky","doi":"10.1007/s11886-024-02101-x","DOIUrl":"10.1007/s11886-024-02101-x","url":null,"abstract":"Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to <math><mo>≤</mo></math> 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0